Geron
GERN
#6333
Rank
A$1.22 B
Marketcap
A$1.91
Share price
-3.05%
Change (1 day)
-69.24%
Change (1 year)

P/E ratio for Geron (GERN)

P/E ratio as of December 2025 (TTM): -10.6

According to Geron's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.5833. At the end of 2024 the company had a P/E ratio of -13.1.

P/E ratio history for Geron from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-13.1105.06%
2023-6.39-4.88%
2022-6.7298.36%
2021-3.39-42.45%
2020-5.8955.88%
2019-3.78-43.33%
2018-6.67-33.33%
2017-10.00-13.04%
2016-11.5-100%
2015> 1000-2.5754493499472E+18%
2014-13.5
2012-2.47

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Eterna Therapeutics
ERNA
-0.0169-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
18.6-275.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
121-1,239.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Incyte
INCY
15.8-249.30%๐Ÿ‡บ๐Ÿ‡ธ USA
CTI BioPharma
CTIC
-15.7 48.09%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.